European Companies Search Engine
Registration · Managing Director (1) · Capital: €25,000 · Shareholder agreement · Seat: Berlin · Legal form: GmbH · Name: AIO-Studien-gGmbH · Proxy policy · Corporate Purpose Hrb17 Oct 2007 German Trade Register Announcements, Germany (15/10/2007)
Overview
Text
AIO-Studien-gGmbH, Berlin (
Unnamed street ??, 14193 Berlin, Germany
). Company: AIO-Studien-gGmbH; Headquarters: Berlin; The aim is to support science and research in the field of internal oncology, in particular the conduct of clinical studies in the field of oncology with a view to improving therapies for oncologically ill patients. To this end, the company will carry out the following activities without being limited to: (a) improving the structure of clinical-oncological research. Clinical research requires the provision of trained personnel for on-site implementation and documentation in the study centres. In particular, "Standard Operation Procedures" (SOPs) for work in study centres should be made available, the training and training of 'Study Nurses' should be made possible, - the development of a curriculum for the training of study assistants, the establishment and provision of a separate "pool" to the study assistant, which can provide support in the individual centres of study work. (b) the establishment of overarching clinical databases. Results/data from clinical trials should be documented in a database of the study' own. In addition, a linkage of study data will be established in an overarching database for studies that have been carried out within a tumor entity either in parallel (with different questions) or one after the other. (c) The structure and organisation of tumour, tissue and serum banks. In addition to the clinical factors, molecular biological and pathological factors should be able to be identified due to potential side effects, but also cost pressures due to the increase in innovative but also high-priced forms of therapy. Necessary steps to this end are - the establishment of real tumor, tissue and serum banks in different locations and for different tumor entities, - creation and support of "virtual tumor banks", - creation of SOPs for asservation and shipping, - assumption of storage and processing fees, - assumption of the costs of sample shipping, - development of a computer system for the correlate of preclinical data with the clinical database. (d) support for preclinical (laboratory) research activities. In addition to the above-mentioned administrative management of the biomaterials, scientific analyses will also be carried out. Share capital: EUR 25,000.00; Representation regulation: If a managing director is appointed, he shall represent the company alone. If several directors have been appointed, the company is represented jointly by two directors or by a managing director in community with one authorized representative. The power of sole representation may be granted. Managing Director: 1. Dr. ??????, ????, *??.??.????, Berlin; with the power to represent the company alone with the power to conduct legal transactions with itself or as a representative of third parties; Legal form: LLC; Social contract of: March 12, 2007; with amendment and recast of September 11, 2007 in Section 2 (Object), Section 3 (Non-profit). As of Section 14, the numbering of the following paragraphs has changed.
This filing was translated from German to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: AIO-Studien-gGmbH, Berlin, Germany.